Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NHS Stock Summary
Top 10 Correlated ETFs
NHS
In the News

NHS: Not A Bad CEF If You're Prepared For A Distribution Cut
Neuberger Berman High Yield Strategies offers a high yield of 14.46%, higher than other closed-end funds investing in junk bonds. The NHS closed-end fund's net asset value has been declining, raising concerns about the sustainability of its distribution. The NHS fund is doing a reasonably good job at protecting itself from default risk, which seems to be increasing with interest rates.

NHS: Don't Ignore The Risk Of More Rate Hikes, Best To DCA Purchases
Neuberger Berman High Yield Strategies offers a remarkable 14.25% distribution yield but has underperformed over the past year due to rising interest rates. The fund primarily invests in junk bonds and aims to provide a high level of current income to investors. The fund employs leverage to boost its yield and total investment returns, but its use of leverage could increase volatility and risk.

NHS: 2023 Rights Offering Results
NHS's 2023 rights offering results are in. The offering was oversubscribed, despite the slim discount to the market price. The "sell and rebuy" strategy worked once again.

83 Monthly-Paying Dividend Stocks And 80 Funds For May
Imagine stocks or funds that pay out their dividends once-a-month! Unlike waiting for quarterly, semi-annual or (ugh) annual payouts, your angst waiting for money is reduced by 300%, or more! These May U.S. exchange-traded monthly-paid (MoPay) dividends, upsides, and net gains include: 1. Stocks by yield (83); 2. Stocks by price upside (30); 3. Closed-End Investments, Exchange-Traded Funds & Notes (CEICs/ETFs/ETNs) by yield >9.56% (80).

NHS: 2023 Rights Offering Quick Notes
Quick notes on Neuberger Berman High Yield Strategies' rights offering this year. Our suggestion is to sell before the ex-rights date and rebuy after the offering.

NHS: Time To Reduce Some Exposure To This High Beta HY CEF
NHS is a fixed income closed end fund. The fund focuses on U.S. high yield bonds, which represent 88% of the portfolio.

NHS: 13% Yield From A High Duration Bond CEF
NHS is a fixed income closed end fund. Over 88% of the fund holdings are fixed rate high yield bonds.

The Month In Closed-End Funds: October 2022
For the first month in three, equity CEFs (+4.49%) on average witnessed plus-side returns, while their fixed income CEF cohorts (-5.07%) suffered a third month of declines in October. Only 17% of all CEFs traded at a premium to their NAV at month end, with 24% of equity CEFs and 11% of fixed income CEFs trading in premium territory.

NHS: Rights Offering Quick Notes
NHS's rights offering is now live. The subscription formula has a floor of a -13% discount, at which point one should not subscribe.

Neuberger Berman High Yield Strategies Fund Announces Monthly Distribution
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Neuberger Berman High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock.
NHS Financial details
NHS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-10-31
Metric | History | 2018-10-31 | 2019-10-31 | 2020-10-31 | 2021-10-31 | 2022-10-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | -0.04 | 1.31 | 0.32 | 1.68 | -1.73 | |
Net income per share | -0.16 | 1.16 | 0.16 | 1.53 | -1.91 | |
Operating cash flow per share | 0.83 | 1.08 | 1.12 | 5.95 | -2.78 | |
Free cash flow per share | 0.83 | 1.08 | 1.12 | 5.95 | -2.78 | |
Cash per share | 0 | 0.04 | 0 | 0 | 0 | |
Book value per share | 12.59 | 12.75 | 12.14 | 10.34 | 9.61 | |
Tangible book value per share | 12.59 | 12.75 | 12.14 | 10.34 | 9.61 | |
Share holders equity per share | 12.59 | 12.75 | 12.14 | 10.34 | 9.61 | |
Interest debt per share | 4.8 | 4.81 | 1.84 | 1.68 | 2.68 | |
Market cap | 199.67M | 231.66M | 203.04M | 230.15M | 143.8M | |
Enterprise value | 289.55M | 320.82M | 235.63M | 259.19M | 189.69M | |
P/E ratio | -64.56 | 10.28 | 67.19 | 8.59 | -4.29 | |
Price to sales ratio | -239.2 | 9.08 | 33.47 | 7.8 | -4.73 | |
POCF ratio | 12.47 | 11.06 | 9.59 | 2.21 | -2.95 | |
PFCF ratio | 12.47 | 11.06 | 9.59 | 2.21 | -2.95 | |
P/B Ratio | 0.82 | 0.94 | 0.89 | 1.27 | 0.85 | |
PTB ratio | 0.82 | 0.94 | 0.89 | 1.27 | 0.85 | |
EV to sales | -346.87 | 12.58 | 38.84 | 8.78 | -6.24 | |
Enterprise value over EBITDA | -2.1K | 14.24 | 77.97 | 9.67 | -5.84 | |
EV to operating cash flow | 18.09 | 15.31 | 11.13 | 2.49 | -3.9 | |
EV to free cash flow | 18.09 | 15.31 | 11.13 | 2.49 | -3.9 | |
Earnings yield | -0.02 | 0.1 | 0.01 | 0.12 | -0.23 | |
Free cash flow yield | 0.08 | 0.09 | 0.1 | 0.45 | -0.34 | |
Debt to equity | 0.37 | 0.36 | 0.14 | 0.16 | 0.27 | |
Debt to assets | 0.24 | 0.23 | 0.09 | 0.1 | 0.16 | |
Net debt to EBITDA | -652.84 | 3.96 | 10.79 | 1.08 | -1.41 | |
Current ratio | 1.21 | 1.15 | 2.86 | 0.66 | 1.72 | |
Interest coverage | -0.05 | 6.63 | 1.43 | 62.23 | -31.93 | |
Income quality | -5.18 | 0.93 | 7 | 3.89 | 1.45 | |
Dividend Yield | 0.08 | 0.08 | 0.1 | 0.07 | 0.13 | |
Payout ratio | -5.21 | 0.81 | 7.02 | 0.61 | -0.54 | |
Sales general and administrative to revenue | -0.79 | 0.05 | 0.23 | 0.03 | -0.02 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 6.73 | 18.24 | 6.61 | 18.87 | 20.33 | |
ROIC | 0 | 0.07 | 0.01 | 0.13 | -0.15 | |
Return on tangible assets | -0.01 | 0.06 | 0.01 | 0.09 | -0.11 | |
Graham Net | -6.61 | -6.53 | -6.69 | -6.19 | -6.99 | |
Working capital | 1.61M | 1.57M | 3.79M | -2.1M | 2.58M | |
Tangible asset value | 243.32M | 247.52M | 229.32M | 181.09M | 168.28M | |
Net current asset value | -125.44M | -123.96M | -124.92M | -107.4M | -120.87M | |
Invested capital | 0.37 | 0.36 | 0.14 | 0.16 | 0.27 | |
Average receivables | 8.59M | 10.15M | 8.43M | 4.97M | 5.15M | |
Average payables | 6.94M | 8.95M | 6.14M | 4.14M | 4.92M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | -4.04K | 158.17 | 349.01 | 51.23 | -74.08 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | -0.09 | 2.31 | 1.05 | 7.12 | -4.93 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.01 | 0.09 | 0.01 | 0.15 | -0.2 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-04-30 for Q2
Metric | History | 2021-04-30 | 2021-10-31 | 2022-04-30 | 2022-10-31 | 2023-04-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | 0 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0 | 0 | 0 | 0 | 0 | |
Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 0 | 0 | 0 | 0 | 0 | |
Enterprise value | 21.78M | 29.03M | 19.32M | 45.89M | 45.78M | |
P/E ratio | 0 | 0 | 0 | 0 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
PTB ratio | 0 | 0 | 0 | 0 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0 | 0 | 0 | 0 | 0 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0.13 | 0.16 | 0.13 | 0.27 | 0.28 | |
Debt to assets | 0.08 | 0.1 | 0.08 | 0.16 | 0.15 | |
Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
Current ratio | 1.57 | 0.66 | 1.65 | 1.72 | 0.88 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 0 | 0 | 0 | 0 | |
ROIC | 0 | 0 | 0 | 0 | 0 | |
Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
Graham Net | 0 | 0 | 0 | 0 | 0 | |
Working capital | 2.54M | -2.1M | 2M | 2.58M | -1.24M | |
Tangible asset value | 185.91M | 181.09M | 153.76M | 168.28M | 166.18M | |
Net current asset value | -97.69M | -107.4M | -94.39M | -120.87M | -123.93M | |
Invested capital | 0.13 | 0.16 | 0.13 | 0.27 | 0.28 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | 0 | 0 | 0 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
NHS Frequently Asked Questions
What is Neuberger Berman High Yield Strategies Fund Inc. stock symbol ?
Neuberger Berman High Yield Strategies Fund Inc. is a US stock , located in New york of Ny and trading under the symbol NHS
What is Neuberger Berman High Yield Strategies Fund Inc. stock quote today ?
Neuberger Berman High Yield Strategies Fund Inc. stock price is $7.4922 today.
Is Neuberger Berman High Yield Strategies Fund Inc. stock public?
Yes, Neuberger Berman High Yield Strategies Fund Inc. is a publicly traded company.